Specialty medication access hinges on a 48-hour window

Twenty minutes. That’s roughly how long I have to review a patient’s history, examine her, explain my diagnosis, write a prescription, and – particularly if I’m prescribing a specialty medication – walk her through what to expect from a drug she’s probably not familiar with.

Roughly three-quarters of drugs now in development are specialty medications, all with their own dosing nuances, monitoring requirements, and need for patient education, among other things. Specialty prescribing is different from regular prescribing because prior authorisation requirements vary by health plan, distribution is often limited to a handful of specialty pharmacies, and financial assistance programmes differ from drug to drug. That means I’m making treatment decisions with different rules every time I prescribe a medication.

This would be a manageable inconvenience if the consequences were only administrative. But they’re not. The vast majority of healthcare providers (HCPs) say that PA-related delays directly harm patient outcomes: diseases progress, avoidable complications arise, and the window for early intervention closes.

The view of specialty prescribing from the exam room

In my experience, patients are most motivated in those first minutes after I write a prescription. What happens in the next 24 to 48 hours often determines whether they start therapy at all. That’s when a prior authorisation may delay getting started, a copay turns out to be higher than expected, or life simply gets in the way. Unfortunately, most support isn’t built to reach patients within that crucial window. By the time support is available, the moment that mattered most has already passed.

And from where I sit as a physician, stalled treatments are invisible. I don’t get a notification when a patient decides that the copay for their specialty medication isn’t affordable, or that making a trip to the pharmacy doesn’t happen in their busy week. I find out at the patient’s next visit, sometimes months later, and maybe with a condition that’s harder to manage than it was when I wrote the first prescription.

Why downstream patient support happens too late

Traditional outreach to improve specialty medication access – a support programme or hub call, a welcome kit, or a benefits verification follow-up – often reach the patient three to five days or more after the prescription is written. Many patients don’t answer calls because they don’t recognise the phone number. Even if they listen to the voicemail, it rarely references the name of their medication or explains why the call is important, so there’s no clear reason for the patient to call back. If they do, patients often encounter a confusing phone tree and then a scripted conversation with a representative who has no context for their specific situation. At that point, frustration may cause them to move on to the next thing demanding their attention that day.

Consider a patient with rheumatoid arthritis. Patients with RA who start biologic therapy early see meaningfully higher remission rates and less joint damage than those whose treatment is delayed. Someone who is newly diagnosed may be a little scared, but hopeful the new medication will help her get back to gardening or picking up her grandchildren.

She leaves the healthcare visit ready to start therapy. Then prior authorisation takes longer than expected. When she gets to the pharmacy, the out-of-pocket cost is a shock. She decides to wait until she understands her diagnosis and medication better. Two months pass and, by the next visit, her disease has progressed and the early window for intervention has closed.

Had patient-specific information like cost and PA requirements been visible at prescribing, her story might have gone differently. The HCP would see the patient’s actual out-of-pocket cost. Prior authorisation status would be trackable in close to real time, rather than disappearing into a payer portal for days. And a prescription wouldn’t bounce around because the drug needed to be routed to a limited distribution network instead of the patient’s regular pharmacy.

Rethinking specialty medication access and when to intervene

I’m not suggesting physicians need one more task added to an already overloaded patient visit. The opposite, actually. The fix means embedding that information directly into the EHR workflow, automatically identifying the PA requirement, calculating the copay, and routing the prescription to a pharmacy that’s eligible to fill it, so none of it falls on the physician or the patient to chase down.

The same logic should apply to what happens next. Rather than waiting to be enrolled in a patient support programme days later, patients could receive automated outreach in the minutes after their visit, while the conversation with their physician is still fresh and their motivation is high. A text message, for instance, can meet a patient where she already is, connecting her to therapy-specific guidance, savings information, enrolment steps, or refill reminders without requiring her to search for answers or work through a phone tree. For patients managing rare or complex diseases, especially those dealing with symptoms like fatigue, a process that asks less of them matters. Support should reduce effort, not add another task.

By recognising that the 48 hours after the physician visit are crucial to the treatment plan for complex and chronic disease and designing automated, proactive outreach for that window, the rest of the journey will get considerably easier for everyone, patients most of all.

About the author

Colin Banas, MD, MHA, is chief medical officer at Timely by DrFirst, an end-to-end prescription engagement platform. Dr Banas spent 17 years as chief medical information officer at VCU Health System, where he also practiced as an internal medicine hospitalist. He has testified before the US Senate and the Office of the National Coordinator on health IT and Meaningful Use, and previously served as a Health IT Fellow at the ONC.